Vanessa Silebi, MD
Infectious Disease · Miami, FLNPI 1780681361
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,420 of the $31,526 with a category attached, or 77.5%. 7 manufacturers reported payments, led by Viiv Healthcare Company at 50.2% of the total. Reporting peaked in 2019 at $11,033 and has fallen 94.0% since, to $667 in 2025. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $111.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$16K
- Gilead$15K
- EMD Serono, Inc.$454
- Amarin Pharma, Inc.$145
- Theratechnologies Inc.$89
- Kowa Pharmaceuticals America, Inc.$35
- plus $21 from 1 others
What the payments were for
- Consulting fees$1,8006%
- Speaking & faculty fees$24,42077%
- Travel & lodging$9923%
- Food & beverage$4,31414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 105 | $15,816 |
| Gilead | 143 | $14,966 |
| EMD Serono, Inc. | 20 | $454 |
| Amarin Pharma, Inc. | 8 | $145 |
| Theratechnologies Inc. | 4 | $89 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Amgen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,526 in reported general payments places this provider in the 90th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 801 | $3,298,755 |
| SerostimSomatropin | 157 | $3,259,858 |
| RukobiaFostemsavir Tromethamine | 47 | $446,898 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 91 | $433,190 |
| JulucaDolutegravir/Rilpivirine | 76 | $272,344 |
| CabenuvaCabotegravir/Rilpivirine | 35 | $238,167 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 56 | $229,180 |
| VascepaIcosapent Ethyl | 172 | $68,588 |
| OzempicSemaglutide | 75 | $67,966 |
| TivicayDolutegravir Sodium | 13 | $63,873 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $48,796 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $38,747 |
| EvotazAtazanavir Sulfate/Cobicistat | 23 | $35,125 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $31,590 |
| MounjaroTirzepatide | 25 | $26,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $14,966 | $3,576,731880 claims |
| EMD Serono, Inc.Serostim | $454 | $3,259,858157 claims |
| Viiv Healthcare CompanyRukobia, Juluca, Cabenuva, Tivicay, Triumeq | $15,816 | $1,091,619194 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $35 | $4,18713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami
- Douglas BrustMiami$359K
- Dushyantha JayaweeraMiami$98K
- Ricardo FrancoMiami$96K
- Lilian AbboMiami$61K
- Jorge MurilloMiami$53K
- Thomas HootonMiami$42K
- Gilberto Torres-MadrizMiami$42K
- Hector BolivarMiami$25K
- Jose Camargo GalvisMiami$19K
- Lennox ArchibaldGainesville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.